Blar i Publikasjoner fra Cristin - St. Olavs hospital på tidsskrift "BMC Endocrine Disorders"
Viser treff 1-1 av 1
-
The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
(Journal article; Peer reviewed, 2011)Background Activation of peroxisome proliferator-activated receptor (PPAR)gamma is associated with bone loss and increased fracture risk, while PPARalpha activation seems to have positive skeletal effects. To further ...